毕得医药
(688073)
| 流通市值：29.43亿 | | | 总市值：61.86亿 |
| 流通股本：4323.42万 | | | 总股本：9088.29万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 627,526,589.12 | 296,374,647.62 | 1,102,010,333.61 | 811,377,889.62 |
| 营业收入 | 627,526,589.12 | 296,374,647.62 | 1,102,010,333.61 | 811,377,889.62 |
| 二、营业总成本 | 522,427,598.32 | 245,523,164.31 | 931,884,986.72 | 696,947,815.87 |
| 营业成本 | 349,840,486.76 | 164,973,511.79 | 646,519,463.42 | 477,309,328.92 |
| 税金及附加 | 3,402,777.89 | 1,298,157.77 | 6,707,012.78 | 4,100,758.52 |
| 销售费用 | 68,419,157.93 | 32,356,689.97 | 126,793,835.1 | 94,315,547.68 |
| 管理费用 | 66,590,352.85 | 32,324,458.52 | 114,648,566.5 | 81,024,454.72 |
| 研发费用 | 29,996,679.58 | 15,144,994.42 | 59,054,452.56 | 45,523,716.19 |
| 财务费用 | 4,178,143.31 | -574,648.16 | -21,838,343.64 | -5,325,990.16 |
| 其中:利息费用 | 3,572,514.02 | 2,245,559.76 | 3,315,789.62 | 4,231,686.97 |
| 其中:利息收入 | 3,379,806.55 | 1,621,814.69 | 22,123,520.01 | 18,154,660.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 742,557.99 | 1,749,038.24 | 3,148,107.01 | 1,269,450.8 |
| 加:投资收益 | 6,707,093.94 | 1,100,276.01 | 1,619,012.09 | 1,509,336.6 |
| 资产处置收益 | 330,567.88 | 240,684.9 | 856,347.2 | 833,396.64 |
| 资产减值损失(新) | -18,647,601.9 | -8,599,090.14 | -33,826,019.95 | -21,223,248.36 |
| 信用减值损失(新) | -3,269,405.25 | -2,479,259.23 | -3,926,949.37 | -3,619,264.95 |
| 其他收益 | 9,676,844.1 | 276,167.35 | 10,338,505.69 | 9,087,820.69 |
| 四、营业利润 | 100,639,047.56 | 43,139,300.44 | 148,334,349.56 | 102,287,565.17 |
| 加:营业外收入 | 507,544.91 | 272,812.28 | 725,289.09 | 334,774.76 |
| 减:营业外支出 | 302,765.56 | 63,069.73 | 1,041,484.67 | 230,780.14 |
| 五、利润总额 | 100,843,826.91 | 43,349,042.99 | 148,018,153.98 | 102,391,559.79 |
| 减:所得税费用 | 27,437,767.37 | 12,655,949.87 | 30,591,990.47 | 18,537,666.99 |
| 六、净利润 | 73,406,059.54 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 73,406,059.54 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 73,406,059.54 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 |
| 扣除非经常损益后的净利润 | 59,163,606.01 | 28,075,051.47 | 104,019,775.67 | 72,390,382.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.84 | 0.34 | 1.32 | 0.94 |
| (二)稀释每股收益 | 0.84 | 0.34 | 1.32 | 0.94 |
| 八、其他综合收益 | 2,453,798.93 | 724,099.55 | -1,641,272.74 | 3,372,706.74 |
| 归属于母公司股东的其他综合收益 | 2,453,798.93 | 724,099.55 | -1,641,272.74 | 3,372,706.74 |
| 九、综合收益总额 | 75,859,858.47 | 31,417,192.67 | 115,784,890.77 | 87,226,599.54 |
| 归属于母公司股东的综合收益总额 | 75,859,858.47 | 31,417,192.67 | 115,784,890.77 | 87,226,599.54 |
| 公告日期 | 2025-08-22 | 2025-04-24 | 2025-04-24 | 2024-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |